
After losing a royalties case against its partner Janssen Biotech in April, Genmab has commenced new arbitration concerning Darzalex Faspro.
Genmab is seeking USD 405m plus interest on accrued milestone payments for Darzalex Faspro, as well as a new 13-year royalties contract backdated to the first commercial sale of the drug.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app